AU2006320670B8 - Methods for the treatment of muscle loss - Google Patents
Methods for the treatment of muscle loss Download PDFInfo
- Publication number
- AU2006320670B8 AU2006320670B8 AU2006320670A AU2006320670A AU2006320670B8 AU 2006320670 B8 AU2006320670 B8 AU 2006320670B8 AU 2006320670 A AU2006320670 A AU 2006320670A AU 2006320670 A AU2006320670 A AU 2006320670A AU 2006320670 B8 AU2006320670 B8 AU 2006320670B8
- Authority
- AU
- Australia
- Prior art keywords
- bcaa
- protein
- use according
- effective amount
- nutritional product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 46
- 238000000034 method Methods 0.000 title claims abstract description 34
- 238000011282 treatment Methods 0.000 title claims description 33
- 150000005693 branched-chain amino acids Chemical class 0.000 claims abstract description 140
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 51
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 51
- 235000016709 nutrition Nutrition 0.000 claims abstract description 40
- 239000002243 precursor Substances 0.000 claims abstract description 27
- 239000002207 metabolite Substances 0.000 claims abstract description 26
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims description 57
- 230000014616 translation Effects 0.000 claims description 54
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 48
- 238000001243 protein synthesis Methods 0.000 claims description 45
- 239000003112 inhibitor Substances 0.000 claims description 33
- 230000015556 catabolic process Effects 0.000 claims description 26
- 102000004877 Insulin Human genes 0.000 claims description 24
- 108090001061 Insulin Proteins 0.000 claims description 24
- 229940125396 insulin Drugs 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 17
- 108010037623 eIF-2 Kinase Proteins 0.000 claims description 15
- 102000010982 eIF-2 Kinase Human genes 0.000 claims description 15
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 13
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 206010006895 Cachexia Diseases 0.000 claims description 10
- 108010016626 Dipeptides Proteins 0.000 claims description 10
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 208000030507 AIDS Diseases 0.000 claims description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 206010022437 insomnia Diseases 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 208000037157 Azotemia Diseases 0.000 claims description 4
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 4
- 206010008748 Chorea Diseases 0.000 claims description 4
- 208000012661 Dyskinesia Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000013016 Hypoglycemia Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 208000012601 choreatic disease Diseases 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 230000001010 compromised effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 206010013663 drug dependence Diseases 0.000 claims description 4
- 208000020694 gallbladder disease Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 230000003908 liver function Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000001076 sarcopenia Diseases 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 4
- 208000009852 uremia Diseases 0.000 claims description 4
- 208000016261 weight loss Diseases 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- ZSOICJZJSRWNHX-ACZMJKKPSA-N Ala-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)[C@H](C)[NH3+] ZSOICJZJSRWNHX-ACZMJKKPSA-N 0.000 claims description 3
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 claims description 3
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 claims description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 3
- KGVHCTWYMPWEGN-UHFFFAOYSA-N glycyl-isoleucine Chemical compound CCC(C)C(C(O)=O)NC(=O)CN KGVHCTWYMPWEGN-UHFFFAOYSA-N 0.000 claims description 3
- 108010050848 glycylleucine Proteins 0.000 claims description 3
- STKYPAFSDFAEPH-LURJTMIESA-N glycylvaline Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 claims description 3
- 108010037850 glycylvaline Proteins 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 claims description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 5
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 claims 2
- 125000001980 alanyl group Chemical group 0.000 claims 1
- 102100026992 Dermcidin Human genes 0.000 description 72
- 101000911659 Homo sapiens Dermcidin Proteins 0.000 description 72
- 230000026731 phosphorylation Effects 0.000 description 32
- 238000006366 phosphorylation reaction Methods 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 25
- 230000017854 proteolysis Effects 0.000 description 23
- 230000004913 activation Effects 0.000 description 20
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 17
- 230000001965 increasing effect Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 15
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 108091008611 Protein Kinase B Proteins 0.000 description 11
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 238000006731 degradation reaction Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 108010064733 Angiotensins Proteins 0.000 description 9
- 102000015427 Angiotensins Human genes 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 7
- 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 description 7
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 7
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000009469 supplementation Effects 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 6
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 206010028289 Muscle atrophy Diseases 0.000 description 5
- 102000038030 PI3Ks Human genes 0.000 description 5
- 108091007960 PI3Ks Proteins 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- -1 enzymes Chemical class 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 201000000585 muscular atrophy Diseases 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 5
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- JSFATNQSLKRBCI-UHFFFAOYSA-N 15-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC(O)C=CC=CCC=CCC=CCCCC(O)=O JSFATNQSLKRBCI-UHFFFAOYSA-N 0.000 description 3
- 102400000344 Angiotensin-1 Human genes 0.000 description 3
- 101800000734 Angiotensin-1 Proteins 0.000 description 3
- 101100232687 Drosophila melanogaster eIF4A gene Proteins 0.000 description 3
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 230000001195 anabolic effect Effects 0.000 description 3
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000004265 eukaryotic small ribosome subunit Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 2
- 230000007730 Akt signaling Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 description 2
- 101710091919 Eukaryotic translation initiation factor 4G Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000001612 cachectic effect Effects 0.000 description 2
- 230000006652 catabolic pathway Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- DKVRNHPCAOHRSI-KQYNXXCUSA-N 7-methyl-GTP Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O DKVRNHPCAOHRSI-KQYNXXCUSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006396 Ephrin-B2 Human genes 0.000 description 1
- 108010044090 Ephrin-B2 Proteins 0.000 description 1
- 108010089791 Eukaryotic Initiation Factor-2 Proteins 0.000 description 1
- 102000008014 Eukaryotic Initiation Factor-2 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 108010090227 Immunoglobulin kappa-Chains Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102100032139 Neuroguidin Human genes 0.000 description 1
- 101710203741 Neuroguidin Proteins 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000010995 Pleckstrin homology domains Human genes 0.000 description 1
- 108050001185 Pleckstrin homology domains Proteins 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 102000003861 Ribosomal protein S6 Human genes 0.000 description 1
- 108090000221 Ribosomal protein S6 Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108010093366 eIF-4B Proteins 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000028499 poly(A) binding Human genes 0.000 description 1
- 108091023021 poly(A) binding Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000009712 regulation of translation Effects 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74109205P | 2005-11-30 | 2005-11-30 | |
| US60/741,092 | 2005-11-30 | ||
| US78094106P | 2006-03-09 | 2006-03-09 | |
| US60/780,941 | 2006-03-09 | ||
| PCT/US2006/045497 WO2007064618A1 (en) | 2005-11-30 | 2006-11-28 | Methods for the treatment of muscle loss |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2006320670A1 AU2006320670A1 (en) | 2007-06-07 |
| AU2006320670B2 AU2006320670B2 (en) | 2010-12-09 |
| AU2006320670B8 true AU2006320670B8 (en) | 2011-04-07 |
Family
ID=37806127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006320670A Ceased AU2006320670B8 (en) | 2005-11-30 | 2006-11-28 | Methods for the treatment of muscle loss |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8329646B2 (https=) |
| EP (1) | EP1957061B1 (https=) |
| JP (1) | JP5260303B2 (https=) |
| CN (1) | CN101316582A (https=) |
| AT (1) | ATE508745T1 (https=) |
| AU (1) | AU2006320670B8 (https=) |
| BR (1) | BRPI0619179A2 (https=) |
| CA (1) | CA2631647A1 (https=) |
| DK (1) | DK1957061T3 (https=) |
| ES (1) | ES2363442T3 (https=) |
| IL (1) | IL191374A0 (https=) |
| MY (1) | MY147489A (https=) |
| PT (1) | PT1957061E (https=) |
| RU (1) | RU2414897C2 (https=) |
| SG (1) | SG163600A1 (https=) |
| WO (1) | WO2007064618A1 (https=) |
| ZA (1) | ZA200805657B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101282657A (zh) * | 2005-10-28 | 2008-10-08 | 雀巢技术公司 | 支链氨基酸的使用方法 |
| DE102007016715A1 (de) * | 2007-04-04 | 2008-10-09 | Evonik Degussa Gmbh | Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren |
| US20110077198A1 (en) * | 2007-11-26 | 2011-03-31 | Michael John Tisdale | Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition |
| CN101939011B (zh) | 2008-02-07 | 2012-10-10 | 雀巢产品技术援助有限公司 | 用于影响由剧烈的体力活动中恢复的组合物和方法 |
| US20090264363A1 (en) * | 2008-03-26 | 2009-10-22 | Ward Loren S | Leucine-Rich Peptide Compositions and Methods for Isolation |
| US20130236447A1 (en) * | 2008-12-23 | 2013-09-12 | Carmel-Haifa University Economic Corp., Ltd. | Cognitive function |
| US20120296403A1 (en) | 2010-02-10 | 2012-11-22 | Novartis Ag | Methods and compounds for muscle growth |
| US20130330423A1 (en) * | 2011-02-25 | 2013-12-12 | Merck Patent Gmbh | Composition to increase joint and/or postural stability |
| RU2454227C1 (ru) * | 2011-04-05 | 2012-06-27 | Федеральное государственное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации | Композиция для восстановления скелетных мышц и кости при скелетной травме |
| RU2631597C2 (ru) | 2011-07-15 | 2017-09-25 | Нусерт Сайенсиз, Инк. | Композиции и способы модулирования метаболических путей |
| CA2863809A1 (en) * | 2012-02-06 | 2013-08-15 | Ajinomoto Co., Inc. | Prophylactic or therapeutic agent for idiopathic inflammatory myopathies |
| US9700071B2 (en) | 2012-03-26 | 2017-07-11 | Axcella Health Inc. | Nutritive fragments, proteins and methods |
| RU2634407C2 (ru) | 2012-03-26 | 2017-10-26 | Эксселла Хелт Инк. | Фрагменты пищевых белков и способы их применения |
| EP2831098A4 (en) | 2012-03-26 | 2016-12-07 | Axcella Health Inc | LOADED NUTRIENT PROTEINS AND METHODS |
| EP2831100A4 (en) | 2012-03-26 | 2016-02-10 | Pronutria Inc | NUTRIENT PROTEINS AND METHOD |
| JP5477413B2 (ja) * | 2012-04-24 | 2014-04-23 | 味の素株式会社 | 分岐鎖アミノ酸の心不全適応 |
| SG10201709195TA (en) | 2012-11-13 | 2017-12-28 | Nusirt Sciences Inc | Compositions and methods for increasing energy metabolism |
| RU2517576C1 (ru) * | 2013-03-06 | 2014-05-27 | Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) | Средство для профилактики и снижения деструкции белков скелетных мышц при их атрофии, вызванной гипокинезией и/или гравитационной разгрузкой |
| ES2844199T3 (es) | 2013-04-16 | 2021-07-21 | Childrens Hospital Philadelphia | Composiciones y métodos para el tratamiento de lesiones cerebrales |
| HK1221609A1 (zh) * | 2013-05-01 | 2017-06-09 | Abbott Laboratories | 增强老化肌肉再生的方法 |
| CN103416760B (zh) * | 2013-08-28 | 2014-09-10 | 山东卫康生物医药科技有限公司 | 治疗和预防肌肉衰减综合症的五谷杂粮全营养配方食品 |
| RU2016110800A (ru) | 2013-09-25 | 2017-10-30 | Пронутриа Биосайенсис, Инк. | Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования |
| KR101668074B1 (ko) * | 2015-02-12 | 2016-10-21 | 전북대학교산학협력단 | Ｐｋｒ 저해제를 유효성분으로 포함하는 기관지 천식의 예방 또는 치료용 조성물 |
| CN105747214A (zh) * | 2016-02-26 | 2016-07-13 | 四川安益生物科技有限公司 | 一种支链氨基酸组合物 |
| JP7077235B2 (ja) * | 2016-12-05 | 2022-05-30 | 大塚製薬株式会社 | 筋萎縮抑制組成物 |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| MX2020001765A (es) | 2017-08-14 | 2020-07-29 | Axcella Health Inc | Composiciones de aminoacidos para el tratamiento de enfermedad hepatica. |
| CN107440126A (zh) * | 2017-09-08 | 2017-12-08 | 天津活力达生物科技有限公司 | 一种缓解运动疲劳的蛋白粉及其制备方法 |
| EP3780973A4 (en) * | 2018-04-18 | 2022-01-26 | Ingenious Ingredients, LP | COMPOSITIONS AND THEIR USE TO PROMOTE MUSCLE GROWTH AND FUNCTION |
| RU2686086C1 (ru) * | 2018-05-17 | 2019-04-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом |
| CN112839643A (zh) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | 用于治疗肌肉中脂肪浸润的组合物及方法 |
| CA3143450A1 (en) * | 2019-06-20 | 2020-12-24 | Societe Des Produits Nestle S.A. | Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids |
| IT201900010437A1 (it) * | 2019-06-28 | 2020-12-28 | Dompe Farm Spa | Composizione per il trattamento del deperimento muscolare |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4780475A (en) * | 1986-02-03 | 1988-10-25 | Cerra Frank B | Preparation for the prevention of catabolism |
| US5716926A (en) * | 1996-07-26 | 1998-02-10 | Paxton K. Beale | Composition of pyruvate and protein and method for increasing protein concentration in a mammal |
| DE19757250A1 (de) * | 1997-12-22 | 1999-07-01 | Forssmann Wolf Georg Prof Dr | Insulin-like growth factor binding protein und seine Verwendung |
| WO1999066917A2 (en) * | 1998-06-23 | 1999-12-29 | Iowa State University Research Foundation, Inc. | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
| WO2001056402A2 (en) * | 2000-02-01 | 2001-08-09 | Muscletech Research And Development Inc. | Alpha lipoic acid based food supplement to increase lean muscle mass and strength |
| WO2003048206A2 (fr) * | 2001-12-04 | 2003-06-12 | Centre National De La Recherche Scientifique | Peptides agonistes de l'hormone de croissance et leurs applications |
| US20030119888A1 (en) * | 1991-11-20 | 2003-06-26 | Allen Ann De Wees | Composition comprising l-arginine as a muscle growth stimulant and use thereof |
| AU2006309040A1 (en) * | 2005-10-28 | 2007-05-10 | Nestec S.A. | Methods for the use of branched chain amino acids |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4491589A (en) * | 1982-05-17 | 1985-01-01 | The Trustees Of Columbia University In The City Of New York | Amino acid solutions for parenteral nutrition and methods of formulation and use |
| US4677121A (en) | 1985-01-22 | 1987-06-30 | The Johns Hopkins University | Method of inhibiting muscle protein degradation |
| US5087472A (en) * | 1990-01-30 | 1992-02-11 | Iowa State University Research Foundation, Inc. | Feed compositions for domestics animals containing hydroxymethylbutyrate |
| JPH03264525A (ja) * | 1990-03-14 | 1991-11-25 | Otsuka Pharmaceut Factory Inc | アミノ酸輸液 |
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| US5817695A (en) * | 1997-12-24 | 1998-10-06 | Pellico; Michael A. | Nutritional product with high fat, low carbohydrate and amino acid imbalance |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| MXPA01002173A (es) * | 1998-08-28 | 2003-07-14 | Scios Inc | Inhibidores de p38-alfa cinasa. |
| US6051236A (en) * | 1998-11-12 | 2000-04-18 | Pacifichealth Laboratories, Inc. | Composition for optimizing muscle performance during exercise |
| US7199124B2 (en) * | 2001-02-02 | 2007-04-03 | Takeda Pharmaceutical Company Limited | JNK inhibitor |
| US6503506B1 (en) * | 2001-08-10 | 2003-01-07 | Millenium Biotechnologies, Inc. | Nutrient therapy for immuno-compromised patients |
| US7744930B2 (en) * | 2002-11-22 | 2010-06-29 | Shaklee Corporation | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass |
| US8703209B2 (en) * | 2003-06-17 | 2014-04-22 | Edward Larry McCleary | Composition and method for modulating hydrogen ion physiology |
| US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
| US20080058324A1 (en) * | 2004-08-25 | 2008-03-06 | Santhera Pharmaceuticals (Schweiz) Ag | Alpha-Keto Carbonyl Calpain Inhibitors |
| US7790688B2 (en) * | 2008-01-11 | 2010-09-07 | Healthspan Solutions, Llc | Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly |
-
2006
- 2006-11-28 US US12/095,477 patent/US8329646B2/en not_active Expired - Fee Related
- 2006-11-28 PT PT06838457T patent/PT1957061E/pt unknown
- 2006-11-28 CN CNA2006800445600A patent/CN101316582A/zh active Pending
- 2006-11-28 WO PCT/US2006/045497 patent/WO2007064618A1/en not_active Ceased
- 2006-11-28 EP EP06838457A patent/EP1957061B1/en not_active Not-in-force
- 2006-11-28 AU AU2006320670A patent/AU2006320670B8/en not_active Ceased
- 2006-11-28 AT AT06838457T patent/ATE508745T1/de active
- 2006-11-28 CA CA002631647A patent/CA2631647A1/en not_active Abandoned
- 2006-11-28 JP JP2008543378A patent/JP5260303B2/ja not_active Expired - Fee Related
- 2006-11-28 DK DK06838457.7T patent/DK1957061T3/da active
- 2006-11-28 SG SG201005000-3A patent/SG163600A1/en unknown
- 2006-11-28 BR BRPI0619179-7A patent/BRPI0619179A2/pt not_active IP Right Cessation
- 2006-11-28 RU RU2008126294/15A patent/RU2414897C2/ru not_active IP Right Cessation
- 2006-11-28 ES ES06838457T patent/ES2363442T3/es active Active
-
2008
- 2008-05-12 IL IL191374A patent/IL191374A0/en unknown
- 2008-05-14 MY MYPI20081593A patent/MY147489A/en unknown
- 2008-06-27 ZA ZA200805657A patent/ZA200805657B/xx unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4780475A (en) * | 1986-02-03 | 1988-10-25 | Cerra Frank B | Preparation for the prevention of catabolism |
| US20030119888A1 (en) * | 1991-11-20 | 2003-06-26 | Allen Ann De Wees | Composition comprising l-arginine as a muscle growth stimulant and use thereof |
| US5716926A (en) * | 1996-07-26 | 1998-02-10 | Paxton K. Beale | Composition of pyruvate and protein and method for increasing protein concentration in a mammal |
| DE19757250A1 (de) * | 1997-12-22 | 1999-07-01 | Forssmann Wolf Georg Prof Dr | Insulin-like growth factor binding protein und seine Verwendung |
| WO1999066917A2 (en) * | 1998-06-23 | 1999-12-29 | Iowa State University Research Foundation, Inc. | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
| WO2001056402A2 (en) * | 2000-02-01 | 2001-08-09 | Muscletech Research And Development Inc. | Alpha lipoic acid based food supplement to increase lean muscle mass and strength |
| WO2003048206A2 (fr) * | 2001-12-04 | 2003-06-12 | Centre National De La Recherche Scientifique | Peptides agonistes de l'hormone de croissance et leurs applications |
| AU2006309040A1 (en) * | 2005-10-28 | 2007-05-10 | Nestec S.A. | Methods for the use of branched chain amino acids |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200805657B (en) | 2009-12-30 |
| DK1957061T3 (da) | 2011-07-25 |
| ES2363442T3 (es) | 2011-08-04 |
| AU2006320670B2 (en) | 2010-12-09 |
| US20090105123A1 (en) | 2009-04-23 |
| EP1957061B1 (en) | 2011-05-11 |
| PT1957061E (pt) | 2011-07-06 |
| RU2414897C2 (ru) | 2011-03-27 |
| WO2007064618A8 (en) | 2008-11-06 |
| SG163600A1 (en) | 2010-08-30 |
| WO2007064618A1 (en) | 2007-06-07 |
| HK1118455A1 (en) | 2009-02-13 |
| AU2006320670A1 (en) | 2007-06-07 |
| CA2631647A1 (en) | 2007-06-07 |
| IL191374A0 (en) | 2009-08-03 |
| BRPI0619179A2 (pt) | 2011-09-13 |
| CN101316582A (zh) | 2008-12-03 |
| RU2008126294A (ru) | 2010-01-10 |
| JP5260303B2 (ja) | 2013-08-14 |
| JP2009517473A (ja) | 2009-04-30 |
| ATE508745T1 (de) | 2011-05-15 |
| MY147489A (en) | 2012-12-14 |
| EP1957061A1 (en) | 2008-08-20 |
| US8329646B2 (en) | 2012-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006320670B8 (en) | Methods for the treatment of muscle loss | |
| Lang et al. | TNF-α impairs heart and skeletal muscle protein synthesis by altering translation initiation | |
| Zheng et al. | RANKL stimulates inducible nitric-oxide synthase expression and nitric oxide production in developing osteoclasts: An autocrine negative feedback mechanism triggered by RANKL-induced interferon-β via NF-κB that restrains osteoclastogenesis and bone resorption | |
| Gonçalves et al. | Clenbuterol suppresses proteasomal and lysosomal proteolysis and atrophy-related genes in denervated rat soleus muscles independently of Akt | |
| CN110087647A (zh) | 氨基酸组合物及肝疾病的治疗方法 | |
| KR20190122806A (ko) | 조합 치료요법용 약학 조성물 | |
| Yoshiji et al. | Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-β with a combination of imatinib mesylate and ACE inhibitor in rats | |
| CA2706656A1 (en) | Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition | |
| Yu et al. | Interaction mechanism of egg white-derived ACE inhibitory peptide TNGIIR with ACE and its effect on the expression of ACE and AT1 receptor | |
| US11389512B2 (en) | Use of low molecular weight fractions of human serum albumin in treating diseases | |
| Grouix et al. | PBI-4050 reduces stellate cell activation and liver fibrosis through modulation of intracellular ATP levels and the liver kinase B1/AMP-activated protein kinase/mammalian target of rapamycin pathway | |
| Ohtsuka et al. | PPA250 [3-(2, 4-Difluorophenyl)-6-{2-[4-(1 H-imidazol-1-ylmethyl) Phenoxy] ethoxy}-2-phenylpyridine], a Novel Orally Effective Inhibitor of the Dimerization of Inducible Nitric-Oxide Synthase, Exhibits an Anti-Inflammatory Effect in Animal Models of Chronic Arthritis | |
| Qiu et al. | Neratinib exerts dual effects on cartilage degradation and osteoclast production in Osteoarthritis by inhibiting the activation of the MAPK/NF-κB signaling pathways | |
| JP2019522658A (ja) | 線維症の治療に使用するためのＷｎｔ阻害剤 | |
| Bar-Or et al. | On the mechanisms of action of the low molecular weight fraction of commercial human serum albumin in osteoarthritis | |
| Ferreri et al. | Renal COX-2, cytokines and 20-HETE: tubular and vascular mechanisms | |
| HK1118455B (en) | Combination comprising at least one amino acid and a pkr inhibitor for use in the treatment of muscle loss | |
| MX2008006902A (en) | Methods for the treatment of muscle loss | |
| Faure et al. | Differential regulation of nitric oxide synthase-II mRNA by growth factors in rat, bovine, and human retinal pigmented epithelial cells | |
| WO2020232095A1 (en) | Polypeptides for treatment of cancer | |
| CN104825487A (zh) | 治疗炎症性关节炎的组合物和方法 | |
| Ehirchiou et al. | OP0127 DEVELOPMENT OF ALLOSTERIC ACTIVATORS OF CYSTATHIONINE G LYASE (CSE) TO AUGMENT HYDROGEN SULFIDE (H2S) AND INHIBIT PATHOLOGIC CARTILAGE CALCIFICATION | |
| Albano | Regulation of the cystine/glutamate antiporter and its contribution to neuronal death | |
| CN118787745A (zh) | 泛jak抑制剂在治疗家族性良性慢性天疱疮中的应用 | |
| WO2006070874A1 (ja) | 低酸素応答促進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| TH | Corrigenda |
Free format text: IN VOL 24, NO 49, PAGE(S) 5716 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME NESTEC S.A,, APPLICATION NO. 2006320670, UNDER INID (71) CORRECT THE APPLICANT NAME TO NESTEC S.A. |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |